How should "RET positive" NSCLC be treated?

作者信息

Smit Egbert F

机构信息

Dept. Thoracic Oncology, Netherlands Cancer Institute & Dept. Pulmonary Diseases, Vrije Universiteit VU Medical Center, Amsterdam, The Netherlands.

出版信息

Lung Cancer. 2017 Jun;108:250-251. doi: 10.1016/j.lungcan.2017.02.006. Epub 2017 Feb 6.

DOI:10.1016/j.lungcan.2017.02.006

PMID:28189265

Abstract

摘要

相似文献

How should "RET positive" NSCLC be treated?

Lung Cancer. 2017 Jun;108:250-251. doi: 10.1016/j.lungcan.2017.02.006. Epub 2017 Feb 6.

[The progress of KIF5B-RET fusion gene in non-small cell lung cancer].

Zhonghua Jie He He Hu Xi Za Zhi. 2013 Jul;36(7):524-6.

Optimal front-line ALK (anaplastic lymphoma kinase) directed therapy.

Lung Cancer. 2017 Jul;109:147-148. doi: 10.1016/j.lungcan.2017.03.008. Epub 2017 Mar 20.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.

Precision Targeted Therapy with BLU-667 for -Driven Cancers.

Cancer Discov. 2018 Jul;8(7):836-849. doi: 10.1158/2159-8290.CD-18-0338. Epub 2018 Apr 15.

Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.

Lung Cancer. 2016 Mar;93:43-6. doi: 10.1016/j.lungcan.2015.12.011. Epub 2015 Dec 30.

Targeting RET alterations in non-small cell lung cancer.

Curr Probl Cancer. 2024 Apr;49:101074. doi: 10.1016/j.currproblcancer.2024.101074. Epub 2024 Mar 16.

Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.

J Thorac Oncol. 2018 Jan;13(1):27-45. doi: 10.1016/j.jtho.2017.10.021. Epub 2017 Nov 8.

Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.

Curr Treat Options Oncol. 2021 Jun 24;22(8):72. doi: 10.1007/s11864-021-00867-8.

The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.

Clin Adv Hematol Oncol. 2015 Mar;13(3):147-9.

引用本文的文献

Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing.

Front Pharmacol. 2019 Mar 12;10:230. doi: 10.3389/fphar.2019.00230. eCollection 2019.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

How should "RET positive" NSCLC be treated?

Lung Cancer. 2017 Jun;108:250-251. doi: 10.1016/j.lungcan.2017.02.006. Epub 2017 Feb 6.

[The progress of KIF5B-RET fusion gene in non-small cell lung cancer].

Zhonghua Jie He He Hu Xi Za Zhi. 2013 Jul;36(7):524-6.

Optimal front-line ALK (anaplastic lymphoma kinase) directed therapy.

Lung Cancer. 2017 Jul;109:147-148. doi: 10.1016/j.lungcan.2017.03.008. Epub 2017 Mar 20.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.

Precision Targeted Therapy with BLU-667 for -Driven Cancers.

Cancer Discov. 2018 Jul;8(7):836-849. doi: 10.1158/2159-8290.CD-18-0338. Epub 2018 Apr 15.

Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.

Lung Cancer. 2016 Mar;93:43-6. doi: 10.1016/j.lungcan.2015.12.011. Epub 2015 Dec 30.

Targeting RET alterations in non-small cell lung cancer.

Curr Probl Cancer. 2024 Apr;49:101074. doi: 10.1016/j.currproblcancer.2024.101074. Epub 2024 Mar 16.

Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.

J Thorac Oncol. 2018 Jan;13(1):27-45. doi: 10.1016/j.jtho.2017.10.021. Epub 2017 Nov 8.

Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.

Curr Treat Options Oncol. 2021 Jun 24;22(8):72. doi: 10.1007/s11864-021-00867-8.

The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.

Clin Adv Hematol Oncol. 2015 Mar;13(3):147-9.

引用本文的文献

Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing.

Front Pharmacol. 2019 Mar 12;10:230. doi: 10.3389/fphar.2019.00230. eCollection 2019.